Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eczema drug shows promise in Mid-Stage trial

NCT ID NCT06395948

Symptom relief Sponsor: Apogee Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 4 times

Summary

This study tests an experimental drug called APG777 in 470 adults with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with creams. The goal is to see if the drug safely reduces skin redness, itching, and rash. Participants receive either APG777 or a placebo for up to 106 weeks, with regular check-ups to track results.

Why investors are watching

Apogee Therapeutics runs this Phase 2 trial of APG777 in 470 patients with moderate-to-severe atopic dermatitis, testing whether the drug eases symptoms better than placebo across two parts. For a small company, this readout is the main evidence that its lead program works in a real patient population.

If it works: A positive result could support moving APG777 into later-stage testing and draw partner or investor interest in the program.

If it fails: A failed or delayed result could set the program back and leave the company with fewer late-stage assets, and most Phase 2 trials do not succeed.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

470 people

The number who actually took part.

Started

Apr 2024

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a diagnosis of AD that has been present for \>=1 year prior to the Screening visit * Moderate-to-severe AD at Screening and Baseline visits * History of inadequate response to treatment with topical medications, or medical determination that topical therapies are inadvisable * Applied a stable dose of non-medicated over-the-counter emollient/moisturizer of their choice on their skin for \>=14 days prior to Baseline visit and agrees to continue using the same moisturizer throughout the study except the day of the study visits. * Have completed itch questionnaires in the electronic diary for \>=4 of 7 days prior to Baseline visit Exclusion Criteria: * Participation in a prior study with APG777. * Prior treatment with protocol-specified monoclonal antibodies (mAbs) * Has used any AD-related topical medications within 7 days prior to Baseline visit. * Has used systemic treatments (other than biologics) and/or phototherapies and/or laser therapy that could affect AD within 4 weeks prior to Baseline visit Note: Other protocol defined inclusion/exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

Contacts and locations

Locations

  • Investigational Site

    Fountain Valley, California, 92708, United States

  • Investigational Site

    Los Angeles, California, 90024, United States

  • Investigational Site

    San Diego, California, 92123, United States

  • Investigational Site

    New Haven, Connecticut, 06519, United States

  • Investigational Site

    Coral Gables, Florida, 33134, United States

  • Investigational Site

    Jacksonville, Florida, 32256, United States

  • Investigational Site

    Margate, Florida, 33063, United States

  • Investigational Site

    Douglasville, Georgia, 30135, United States

  • Investigational Site

    Chicago, Illinois, 60657, United States

  • Investigational Site

    Skokie, Illinois, 60077, United States

  • Investigational Site

    West Lafayette, Indiana, 47906, United States

  • Investigational Site

    Bowling Green, Kentucky, 42104, United States

  • Investigational Site

    Rockville, Maryland, 20850, United States

  • Investigational Site

    Detroit, Michigan, 48202, United States

  • Investigational Site

    Troy, Michigan, 48084, United States

  • Investigational Site

    Portsmouth, New Hampshire, 13801, United States

  • Investigational Site

    New York, New York, 10023, United States

  • Investigational Site

    Wilmington, North Carolina, 28403, United States

  • Investigational Site

    Boardman, Ohio, 44512, United States

  • Investigational Site

    Mason, Ohio, 45040, United States

  • Investigational Site

    Portland, Oregon, 97201, United States

  • Investigational Site

    Pittsburgh, Pennsylvania, 15213, United States

  • Investigational Site

    Charleston, South Carolina, 29425, United States

  • Investigational Site

    Nashville, Tennessee, 37215, United States

  • Investigational Site

    Dallas, Texas, 75230, United States

  • Investigational Site

    Dallas, Texas, 75235, United States

  • Investigational Site

    San Antonio, Texas, 78213, United States

  • Investigational Site

    Norfolk, Virginia, 23502, United States

  • Investigational Site

    Mill Creek, Washington, 98012, United States

  • Investigational Site

    Calgary, Alberta, T2J 7E1, Canada

  • Investigational Site

    Calgary, Alberta, T3E 0B2, Canada

  • Investigational Site

    Edmonton, Alberta, T5J 3S9, Canada

  • Investigational Site

    Vancouver, British Columbia, V5Z 4E8, Canada

  • Investigational Site

    Winnipeg, Manitoba, R3M 3Z4, Canada

  • Investigational Site

    Fredericton, New Brunswick, E3B 1G9, Canada

  • Investigational Site

    Ajax, Ontario, L1S 7K8, Canada

  • Investigational Site

    Markham, Ontario, L3P 1X3, Canada

  • Investigational Site

    Mississauga, Ontario, L4Y 4C5, Canada

  • Investigational Site

    Ottawa, Ontario, K1K 4L2, Canada

  • Investigational Site

    Peterborough, Ontario, K9J 5K2, Canada

  • Investigational Site

    Toronto, Ontario, M3B 0A7, Canada

  • Investigational Site

    Toronto, Ontario, M4E 2Y9, Canada

  • Investigational Site

    Toronto, Ontario, M4W 2N4, Canada

  • Investigational Site

    Montreal, Quebec, H2X 2V1, Canada

  • Investigational Site

    Québec, Quebec, G1V4X7, Canada

  • Investigational Site

    Prague, 10000, Czechia

  • Investigational Site

    Prague, 10034, Czechia

  • Investigational Site

    Prague, 11000, Czechia

  • Investigational Site

    Prague, 15006, Czechia

  • Investigational Site

    Prague, 16000, Czechia

  • Investigational Site

    Rouen, Normandy, 76031, France

  • Investigational Site

    Martigues, 13500, France

  • Investigational Site

    Nantes, 44093, France

  • Investigational Site

    Freiburg im Breisgau, Baden-Wurttemberg, 79104, Germany

  • Investigational Site

    Heidelberg, Baden-Wurttemberg, 69120, Germany

  • Investigational Site

    Tübingen, Baden-Wurttemberg, 72076, Germany

  • Investigational Site

    Augsburg, Bavaria, 86179, Germany

  • Investigational Site

    München, Bavaria, 81377, Germany

  • Investigational Site

    Blankenfelde-Mahlow, Brandenburg, 15831, Germany

  • Investigational Site

    Darmstadt, Hesse, 64283, Germany

  • Investigational Site

    Frankfurt am Main, Hesse, 60590, Germany

  • Investigational Site

    Bad Bentheim, Lower Saxony, 48455, Germany

  • Investigational Site

    Münster, North Rhine Westfalia, 48149, Germany

  • Investigational Site

    Dresden, Saxony, 01307, Germany

  • Investigational Site

    Kiel, Schleswig-Holstein, 24105, Germany

  • Investigational Site

    Lübeck, Schleswig-Holstein, 23538, Germany

  • Investigational Site

    Berlin, 10117, Germany

  • Investigational Site

    Hamburg, 20246, Germany

  • Investigational Site

    Hamburg, 20354, Germany

  • Investigational Site

    Debrecen, Hajdú-Bihar, 4032, Hungary

  • Investigational Site

    Budapest, 1085, Hungary

  • Investigational Site

    Szeged, 6720, Hungary

  • Investigational Site

    Wroclaw, Lower Silesian Voivodeship, 50-450, Poland

  • Investigational Site

    Wroclaw, Lower Silesian Voivodeship, 51-503, Poland

  • Investigational Site

    Lublin, Lublin Voivodeship, 20-573, Poland

  • Investigational Site

    Warsaw, Masovian Voivodeship, 01-595, Poland

  • Investigational Site

    Warsaw, Masovian Voivodeship, 02-482, Poland

  • Investigational Site

    Gdansk, Pomeranian Voivodeship, 80-546, Poland

  • Investigational Site

    Katowice, Silesian Voivodeship, 40-600, Poland

  • Investigational Site

    Sosnowiec, Silesian Voivodeship, 41-218, Poland

  • Investigational Site

    Szczecin, West Pomeranian Voivodeship, 71-500, Poland

  • Investigational Site

    Krakow, Woj. Małopolskie, 30-727, Poland

  • Investigational Site

    Lodz, Łódź Voivodeship, 90-338, Poland

  • Investigational Site

    Santiago de Compostela, A Coruña, 15706, Spain

  • Investigational Site

    Badalona, Barcelona, 08916, Spain

  • Investigational Site

    Las Palmas de Gran Canaria, Canary Islands, 35010, Spain

  • Investigational Site

    Alicante, 03010, Spain

  • Investigational Site

    Barcelona, 08041, Spain

  • Investigational Site

    Madrid, 28006, Spain

  • Investigational Site

    Madrid, 28040, Spain

  • Investigational Site

    Zaragoza, 50009, Spain

  • Investigational Site

    Salford, Greater Manchester, M6 8HD, United Kingdom

  • Investigational Site

    Dudley, West Midlands, DY1 2HQ, United Kingdom

  • Investigational Site

    London, SE1 9RT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.